Arterial events in cancer patients—the case of acute coronary thrombosis

Ohad Oren, Joerg Herrmann

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Patients with cancer are at high risk for both venous and arterial thrombotic complications. A variety of factors account for the greater thrombotic risk, including the underlying malignancy and numerous cancer-directed therapies. The occurrence of an acute thrombotic event in patients with cancer is associated with substantial morbidity and mortality. Acute coronary syndrome (ACS) represents a particularly important cardiovascular complication in cancer patients. With cardio-vascular risk factors becoming more prevalent in an aging cancer population that is surviving longer, questions pertaining to the appropriate management of vascular toxicity are likely to assume even greater value in the coming years. In this article, we review the current understanding of ACS in patients with cancer. The predisposition to thrombosis in a malignant host and the cancer treatments most commonly associated with vascular toxicity are reviewed. Risk prediction and management strategies are discussed, and discrepancies in the clinical evidence are highlighted.

Original languageEnglish (US)
Pages (from-to)S4367-S4385
JournalJournal of Thoracic Disease
Volume10
DOIs
StatePublished - Dec 1 2018

Fingerprint

Coronary Thrombosis
Neoplasms
Acute Coronary Syndrome
Blood Vessels
Risk Management
Thrombosis
Morbidity
Mortality

Keywords

  • Acute coronary syndrome (ACS)
  • Anti-cancer therapy
  • Coronary artery disease
  • Radiation therapy
  • Thromboembolism

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Arterial events in cancer patients—the case of acute coronary thrombosis. / Oren, Ohad; Herrmann, Joerg.

In: Journal of Thoracic Disease, Vol. 10, 01.12.2018, p. S4367-S4385.

Research output: Contribution to journalReview article

@article{08f832190082485b9f42bb6d3ec934a0,
title = "Arterial events in cancer patients—the case of acute coronary thrombosis",
abstract = "Patients with cancer are at high risk for both venous and arterial thrombotic complications. A variety of factors account for the greater thrombotic risk, including the underlying malignancy and numerous cancer-directed therapies. The occurrence of an acute thrombotic event in patients with cancer is associated with substantial morbidity and mortality. Acute coronary syndrome (ACS) represents a particularly important cardiovascular complication in cancer patients. With cardio-vascular risk factors becoming more prevalent in an aging cancer population that is surviving longer, questions pertaining to the appropriate management of vascular toxicity are likely to assume even greater value in the coming years. In this article, we review the current understanding of ACS in patients with cancer. The predisposition to thrombosis in a malignant host and the cancer treatments most commonly associated with vascular toxicity are reviewed. Risk prediction and management strategies are discussed, and discrepancies in the clinical evidence are highlighted.",
keywords = "Acute coronary syndrome (ACS), Anti-cancer therapy, Coronary artery disease, Radiation therapy, Thromboembolism",
author = "Ohad Oren and Joerg Herrmann",
year = "2018",
month = "12",
day = "1",
doi = "10.21037/jtd.2018.12.79",
language = "English (US)",
volume = "10",
pages = "S4367--S4385",
journal = "Journal of Thoracic Disease",
issn = "2072-1439",
publisher = "Pioneer Bioscience Publishing Company (PBPC)",

}

TY - JOUR

T1 - Arterial events in cancer patients—the case of acute coronary thrombosis

AU - Oren, Ohad

AU - Herrmann, Joerg

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Patients with cancer are at high risk for both venous and arterial thrombotic complications. A variety of factors account for the greater thrombotic risk, including the underlying malignancy and numerous cancer-directed therapies. The occurrence of an acute thrombotic event in patients with cancer is associated with substantial morbidity and mortality. Acute coronary syndrome (ACS) represents a particularly important cardiovascular complication in cancer patients. With cardio-vascular risk factors becoming more prevalent in an aging cancer population that is surviving longer, questions pertaining to the appropriate management of vascular toxicity are likely to assume even greater value in the coming years. In this article, we review the current understanding of ACS in patients with cancer. The predisposition to thrombosis in a malignant host and the cancer treatments most commonly associated with vascular toxicity are reviewed. Risk prediction and management strategies are discussed, and discrepancies in the clinical evidence are highlighted.

AB - Patients with cancer are at high risk for both venous and arterial thrombotic complications. A variety of factors account for the greater thrombotic risk, including the underlying malignancy and numerous cancer-directed therapies. The occurrence of an acute thrombotic event in patients with cancer is associated with substantial morbidity and mortality. Acute coronary syndrome (ACS) represents a particularly important cardiovascular complication in cancer patients. With cardio-vascular risk factors becoming more prevalent in an aging cancer population that is surviving longer, questions pertaining to the appropriate management of vascular toxicity are likely to assume even greater value in the coming years. In this article, we review the current understanding of ACS in patients with cancer. The predisposition to thrombosis in a malignant host and the cancer treatments most commonly associated with vascular toxicity are reviewed. Risk prediction and management strategies are discussed, and discrepancies in the clinical evidence are highlighted.

KW - Acute coronary syndrome (ACS)

KW - Anti-cancer therapy

KW - Coronary artery disease

KW - Radiation therapy

KW - Thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=85059864890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059864890&partnerID=8YFLogxK

U2 - 10.21037/jtd.2018.12.79

DO - 10.21037/jtd.2018.12.79

M3 - Review article

VL - 10

SP - S4367-S4385

JO - Journal of Thoracic Disease

JF - Journal of Thoracic Disease

SN - 2072-1439

ER -